PMID- 35930188
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230421
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 13
IP  - 9
DP  - 2022 Sep
TI  - Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 
      Diabetes Suboptimally Controlled by Basal Insulin in the US.
PG  - 1659-1670
LID - 10.1007/s13300-022-01300-5 [doi]
AB  - INTRODUCTION: Many people with type 2 diabetes mellitus (T2DM) experience 
      suboptimal glycemic control and require therapy advancement. This 
      cost-effectiveness analysis was conducted to compare iGlarLixi (insulin glargine 
      100 U/mL plus lixisenatide) versus BIAsp 30 (biphasic insulin aspart 30) in 
      people with T2DM suboptimally controlled with basal insulin. METHODS: The IQVIA 
      Core Diabetes Model was used to estimate lifetime costs and outcomes for people 
      with T2DM from a US healthcare payer perspective. Initial clinical data were 
      based on the phase 3 randomized, open-label, active-controlled SoliMix clinical 
      study, which compared the efficacy and safety of once-daily iGlarLixi with 
      twice-daily BIAsp 30. Lifetime costs (US$) and quality-adjusted life-years 
      (QALYs) were predicted, and the incremental cost-effectiveness ratio (ICER) for 
      iGlarLixi versus BIAsp 30 was estimated; the willingness-to-pay threshold was 
      considered to be $50,000. A subgroup analysis considered people with T2DM 
      aged >/= 65 years. RESULTS: Estimated QALYs gained were slightly higher with 
      iGlarLixi compared with BIAsp 30 (9.3 vs. 9.2), with lower costs for iGlarLixi 
      ($117,854 vs. $120,109); the ICER for iGlarLixi was therefore considered dominant 
      over BIAsp 30 in the base case. Key drivers for cost savings were the higher dose 
      and twice-daily administration for BIAsp 30 versus once-daily administration for 
      iGlarLixi. The robustness of the base-case results was confirmed by sensitivity 
      and scenario analyses. Results were similar in a subgroup of people with T2DM 
      aged >/= 65 years. CONCLUSION: In people with T2DM with suboptimal glycemic control 
      on basal insulin, iGlarLixi confers improved QALYs and reduced costs compared 
      with BIAsp 30.
CI  - (c) 2022. The Author(s).
FAU - Shao, Hui
AU  - Shao H
AD  - University of Florida's College of Pharmacy, Gainesville, FL, USA.
FAU - Alsaleh, Abdul Jabbar Omar
AU  - Alsaleh AJO
AD  - Sanofi, Milan, Italy.
FAU - Dex, Terry
AU  - Dex T
AD  - Sanofi, Bridgewater, NJ, USA.
FAU - Lew, Elisheva
AU  - Lew E
AD  - Sanofi, Paris, France.
FAU - Fonseca, Vivian
AU  - Fonseca V
AD  - Tulane University School of Medicine, New Orleans, LA, USA. vfonseca@tulane.edu.
AD  - Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA, 
      70112, USA. vfonseca@tulane.edu.
LA  - eng
GR  - U54 GM104940/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20220805
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC9399315
OTO - NOTNLM
OT  - BIAsp 30
OT  - Cost-effectiveness
OT  - Cost-utility
OT  - Older adults
OT  - Premix
OT  - SoliMix trial
OT  - Type 2 diabetes
OT  - United States
OT  - iGlarLixi
EDAT- 2022/08/06 06:00
MHDA- 2022/08/06 06:01
PMCR- 2022/08/05
CRDT- 2022/08/05 11:20
PHST- 2022/05/18 00:00 [received]
PHST- 2022/07/15 00:00 [accepted]
PHST- 2022/08/06 06:00 [pubmed]
PHST- 2022/08/06 06:01 [medline]
PHST- 2022/08/05 11:20 [entrez]
PHST- 2022/08/05 00:00 [pmc-release]
AID - 10.1007/s13300-022-01300-5 [pii]
AID - 1300 [pii]
AID - 10.1007/s13300-022-01300-5 [doi]
PST - ppublish
SO  - Diabetes Ther. 2022 Sep;13(9):1659-1670. doi: 10.1007/s13300-022-01300-5. Epub 
      2022 Aug 5.